INVO Fertility (IVF) Company Report

INVO Fertility's CEO, Steve Shum, stated on February 4, 2026, that the company is in its strongest fundamental position in history, attributing this to operational progress, disciplined capital management, and a clear growth strategy.
The company currently operates three fertility clinics generating positive operational cash flow and is nearing the acquisition of a fourth clinic in Indianapolis.
The combined pro forma annualized revenue run rate from all clinics, including the Indianapolis acquisition, is approximately $9 million.
INVO Fertility anticipates strong growth in 2026 through acquisitions and organic expansion, supported by a balance sheet that is the strongest it has been in over three years.

3 days ago

Press Release

INVO Fertility Enters Warrant Inducement Agreement for $7.5 Million

IVF

INVO Fertility Inc. (IVF) entered into a warrant inducement agreement on January 28, 2026, with an investor for the immediate exercise of certain outstanding warrants.
The investor agreed to exercise 4,733,728 shares of common stock from December 2025 Warrants at a reduced exercise price of $1.59 per share, which is expected to generate approximately $7.5 million in gross proceeds for the company.
In consideration for the exercise, INVO Fertility will issue new unregistered warrants to purchase 9,467,456 shares of common stock at an exercise price of $1.59 per share, with these new warrants being subject to shareholder approval.
Maxim Group LLC is serving as the exclusive Financial Advisor for the transaction and will receive a fee equal to 6.5% of the gross proceeds from the exercise of the existing warrants.

7 days ago

8-K

INVO Fertility Enters into Warrant Inducement Agreement

IVF

INVO Fertility Inc. (IVF) has entered into a warrant inducement agreement with an investor for the immediate exercise of certain outstanding December 2025 Warrants.
The exercise price of the outstanding December 2025 Warrants has been reduced to $1.59, leading to the purchase of an aggregate of 4,733,728 shares of the Company’s common stock.
This transaction is expected to generate approximately $7.5 million in gross proceeds for the company.
In consideration for the immediate exercise, the Company also agreed to issue unregistered New Warrants to the investor, allowing the purchase of an aggregate of 9,467,456 shares at an exercise price of $1.59 per share, subject to shareholder approval.
The closing of these warrant exercise transactions is anticipated to occur on or about January 30, 2026.

Jan 29, 2026, 1:30 PM

Press Release

INVO Fertility Announces Executive Leadership Changes

IVF

Management Change

CFO Change

New Projects/Investments

INVO Fertility announced executive leadership changes on December 30, 2025, to align its human resources with the company's growth strategy.
Terah Krigsvold, who previously served as controller, has been appointed as the new Chief Financial Officer.
Andrea Goren, the former CFO, has been appointed as Chief Business Officer and Chief Executive Officer of INVO Centers LLC.
These changes are intended to strengthen the company's ability to execute its plan to grow the business through acquisitions and new clinic launches, and to reach profitability.

Dec 30, 2025, 9:05 PM

Press Release

INVO Fertility Announces $4.0 Million Private Placement

IVF

INVO Fertility, Inc. announced a private placement of securities with a single institutional investor.
The offering includes 2,366,864 shares of common stock (or pre-funded warrants) and warrants to purchase up to 4,733,728 shares of common stock.
The combined effective offering price for each share (or pre-funded warrant) and accompanying warrants is $1.69.
The company expects to receive approximately $4.0 million in gross proceeds from the offering, which is anticipated to close around December 3, 2025.

Dec 5, 2025, 10:01 PM

8-K

INVO Fertility Announces 1-for-8 Reverse Stock Split

IVF

Delisting/Listing Issues

INVO Fertility, Inc. (IVF) announced a 1-for-8 reverse stock split that became effective at 12:01 a.m. Eastern Time on November 28, 2025.
Commencing with the opening of trading on November 28, 2025, the company's common stock began trading on a post-split basis under the same trading symbol, "IVF".
Immediately after the reverse stock split, the company will have approximately 1,891,151 shares of common stock issued and outstanding and 6,250,000 authorized shares.
Fractional shares resulting from the split were rounded up to the next whole share, and the new CUSIP number for the common stock is 44984F807.

Dec 3, 2025, 9:46 PM

8-K

INVO Fertility Announces Intent to Acquire Family Beginnings

IVF

M&A

New Projects/Investments

INVO Fertility (Nasdaq: IVF) announced its intent to acquire Family Beginnings, P.C., a fertility clinic serving patients across Indiana and the broader Midwest.
This planned acquisition is INVO's second acquisition and reflects the Company's strategic initiative to build a nationwide network of fertility centers.
Family Beginnings' founder, Dr. James Donahue, is an early adopter and advocate of INVO's INVOcell technology.
The acquisition is subject to completion of customary due diligence and negotiation of definitive purchase agreements, with the transaction expected to close in the near-term.

Nov 28, 2025, 6:05 PM

Press Release

INVO Fertility, Inc. Announces Third Quarter 2025 Financial Results

IVF

Earnings

Revenue Acceleration/Inflection

New Projects/Investments

INVO Fertility, Inc. reported total revenue of $1,757,094 for Q3 2025, marking a 23% increase compared to Q3 2024.
The company's net loss was $(2.6) million in Q3 2025, compared to $(1.6) million in the prior year, with Adjusted EBITDA at $(947,568).
Organic clinic growth reached 23% in Q3 2025, driven by increased patient flow, and INVOcell device revenue saw a 130% year-over-year increase.
INVO Fertility is actively pursuing an acquisition strategy, with plans to complete at least one acquisition in the coming months, and highlighted recent federal policy updates that expand access to IVF coverage.

Nov 17, 2025, 1:43 PM

8-K

INVO Fertility, Inc. Exchanges Convertible Debenture for Preferred Stock

IVF

Convertible Preferred Issuance

INVO FERTILITY, INC. (IVF) entered into an Exchange Agreement with Five Narrow Lane LP (FNL) on September 29, 2025, to convert a debt instrument into equity.
FNL exchanged its Second Amended and Restated Senior Secured Convertible Debenture for Series C-2 Convertible Preferred Stock.
The Company issued Series C-2 Preferred Stock with an aggregate stated value of $1,334,000 and an additional 467 shares of Series C-2 Preferred Stock to FNL.
This transaction resulted in the full extinguishment of the Second Amended and Restated Debenture.